🏛️ Verified NIH Record • Updated 2026-07-10
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) (NCT06750432)
A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer's Disease
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: ProMis Neurosciences, Inc
🩺 Plain-English Summary (8th-Grade Level)
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
Who can join: Review the eligibility criteria below.
Location: Irvine Center for Clinical Research — Irvine, California
Age range: 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- Irvine Center for Clinical Research — Irvine, California
- Healthy Brain Research — Long Beach, California
- JEM Research Institute — Atlantis, Florida
- Quantum Laboratories — Deerfield Beach, Florida
- Brain Matters Research — Delray Beach, Florida
- Finlay Medical Research — Miami, Florida
- Gonzalez MD and Aswad MD Health Services, Optimus U Corp — Miami, Florida
- Renstar Medical Research — Ocala, Florida
- Charter Research — Orlando, Florida
- Alzheimer's Research and Treatment Center — Stuart, Florida
- Charter Research — The Villages, Florida
- Alzheimer's Research and Treatment Center — Wellington, Florida
- Conquest Research, LLC — Winter Park, Florida
- Columbus Memory Center, LLC — Columbus, Georgia
- CenExel iResearch, LLC — Decatur, Georgia
- Headlands Eastern MA LLC — Plymouth, Massachusetts
- Advanced Memory Research Institute of NJ — Toms River, New Jersey
- Alzheimer's Disease Research Center — Albany, New York
- Flourish Research — Matthews, North Carolina
- Neuro Behavioral Clinical Research, Inc. — North Canton, Ohio
- Keystone Clinical Studies, LLC — Plymouth Meeting, Pennsylvania
- Kerwin Medical Center — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer Disease, Early Onset
- Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study — Winston-Salem, North Carolina
- Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease — Baltimore, Maryland
- Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease — Chandler, Arizona
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau — New York, New York
- Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD — Los Angeles, California
Explore by condition: All Alzheimer Disease, Early Onset clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.